RU2004133347A - Лекарственное средство для профилактики и/или лечения хронического отторжения - Google Patents

Лекарственное средство для профилактики и/или лечения хронического отторжения Download PDF

Info

Publication number
RU2004133347A
RU2004133347A RU2004133347/14A RU2004133347A RU2004133347A RU 2004133347 A RU2004133347 A RU 2004133347A RU 2004133347/14 A RU2004133347/14 A RU 2004133347/14A RU 2004133347 A RU2004133347 A RU 2004133347A RU 2004133347 A RU2004133347 A RU 2004133347A
Authority
RU
Russia
Prior art keywords
prevention
intended
tacrolim
effective amount
therapeutically effective
Prior art date
Application number
RU2004133347/14A
Other languages
English (en)
Russian (ru)
Inventor
Масаказу КОБАЯСИ (US)
Масаказу КОБАЯСИ
Хонгси ДЗИАНГ (US)
Хонгси ДЗИАНГ
Фан ПАН (US)
Фан ПАН
Лори ЭРИКСОН (US)
Лори ЭРИКСОН
Аарон ЭББЗ (US)
Аарон ЭББЗ
Кармен УИНН (US)
Кармен УИНН
Original Assignee
Фудзисава Фармасьютикал Ко.,Лтд. (Jp)
Фудзисава Фармасьютикал Ко.,Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко.,Лтд. (Jp), Фудзисава Фармасьютикал Ко.,Лтд. filed Critical Фудзисава Фармасьютикал Ко.,Лтд. (Jp)
Publication of RU2004133347A publication Critical patent/RU2004133347A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2004133347/14A 2002-04-16 2003-04-14 Лекарственное средство для профилактики и/или лечения хронического отторжения RU2004133347A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37241902P 2002-04-16 2002-04-16
US60/372,419 2002-04-16

Publications (1)

Publication Number Publication Date
RU2004133347A true RU2004133347A (ru) 2005-05-10

Family

ID=29250850

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004133347/14A RU2004133347A (ru) 2002-04-16 2003-04-14 Лекарственное средство для профилактики и/или лечения хронического отторжения

Country Status (18)

Country Link
US (2) US20030232867A1 (https=)
EP (1) EP1494669A1 (https=)
JP (1) JP2005526107A (https=)
KR (1) KR20040101381A (https=)
CN (1) CN1646122A (https=)
AR (1) AR039416A1 (https=)
AU (1) AU2003223119A1 (https=)
BR (1) BR0309427A (https=)
CA (1) CA2481184A1 (https=)
IL (1) IL164185A0 (https=)
MX (1) MXPA04010170A (https=)
NO (1) NO20044272L (https=)
NZ (1) NZ535692A (https=)
PL (1) PL372902A1 (https=)
RU (1) RU2004133347A (https=)
TW (1) TW200306825A (https=)
WO (1) WO2003086391A1 (https=)
ZA (1) ZA200407813B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2965756B1 (en) 2009-04-22 2018-10-10 AskAt Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) * 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの3つの成分の塩
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus

Also Published As

Publication number Publication date
IL164185A0 (en) 2005-12-18
ZA200407813B (en) 2005-10-18
CN1646122A (zh) 2005-07-27
BR0309427A (pt) 2005-02-01
AU2003223119A1 (en) 2003-10-27
NZ535692A (en) 2006-07-28
AR039416A1 (es) 2005-02-16
WO2003086391A1 (en) 2003-10-23
TW200306825A (en) 2003-12-01
US20060211725A1 (en) 2006-09-21
MXPA04010170A (es) 2005-02-03
CA2481184A1 (en) 2003-10-23
JP2005526107A (ja) 2005-09-02
KR20040101381A (ko) 2004-12-02
EP1494669A1 (en) 2005-01-12
NO20044272L (no) 2004-12-15
US20030232867A1 (en) 2003-12-18
PL372902A1 (en) 2005-08-08

Similar Documents

Publication Publication Date Title
RU2004133347A (ru) Лекарственное средство для профилактики и/или лечения хронического отторжения
ES2521672T3 (es) Formulaciones farmacéuticas para el tratamiento del cáncer
JP2005526107A5 (https=)
US20090137527A1 (en) Compositions and methods for modulating immune function
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
JP2006514021A5 (https=)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
ES2089027T3 (es) Forma de dosificacion transmucosica.
RU2008133654A (ru) Способ и лекарственное средство для лечения тяжелой сердечной недостаточности
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
US20110053991A1 (en) Treatment of Histone Deacetylase Mediated Disorders
AR033953A1 (es) Una forma de droga libre en particulas de un compuesto de beta-carbolina , su composicion farmaceutica, metodo de tratamiento de la disfuncion sexual , metodo para fabricar dicha forma del compuesto y uso de las particulas
RU2001119054A (ru) Калиевая соль (S)-омепразола
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2009123536A (ru) Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
AU2003240113B2 (en) Formulation of nefopam and its use in the treatment of pain
RU2010138650A (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
RU2004126447A (ru) Лечение ревматоидного артрита
TW201000098A (en) Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for the treatment of severe malaria
US6455555B1 (en) Anti-HIV infection agents and method for treating HIV infection
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070619